Staffing and recruiting firm Vector Talent sees oligonucleotides “breaking out” of rare disease, and GLP-1s still driving most new fill-finish demand next year.
The acquisition of the Chemistry, Manufacturing and Controls team adds more than 35 specialists in biologics development, production oversight, and regulatory strategy.
This presentation addresses key considerations for developing and validating ADC-specific analytical methods, including DAR distribution, free payload, conjugational heterogeneity, product-related impurities and functional potency.